Fig. 2: Chronology of the evolution of intra-host mutations. | Nature Communications

Fig. 2: Chronology of the evolution of intra-host mutations.

From: Cumulative SARS-CoV-2 mutations and corresponding changes in immunity in an immunocompromised patient indicate viral evolution within the host

Fig. 2

The emergence of intra-host mutations in an immunocompromised patient with adequate humoral and lacking cellular immune response. The study period comprised 140 days of almost permanent viral shedding. High-quality next-generation sequences could be obtained at 14 time-points during the seven-month study period (starting on day 73, ending on day 207 with the last SARS-CoV-2 positive swab) and disclosed the chronological development of mutational events of SARS-CoV-2 as an answer to a unilateral immune response with strong antibody answer but lack of specific T-cells. RTX therapy, rituximab therapy; IVIG therapy, intravenous immune globulin therapy; single-event, temporary mutation. Source data are provided as a Source Data file.

Back to article page